Primary Peritoneal Carcinosarcoma
Associated Genetic Biomarkers
NCI Definition: An extremely rare and highly aggressive malignant neoplasm arising from the peritoneum. Morphologically, it is a high grade tumor, composed of carcinomatous and sarcomatous elements. 
There are 8 clinical trials for primary peritoneal carcinosarcoma, of which 7 are open and 1 is completed or closed. Of the trials that contain primary peritoneal carcinosarcoma as an inclusion criterion, 2 are phase 1 (2 open), 3 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open).
NT5E is the most frequent gene inclusion criterion for primary peritoneal carcinosarcoma clinical trials .
Cisplatin, paclitaxel, and pembrolizumab are the most common interventions in primary peritoneal carcinosarcoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.